Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma.

NCT06642506 is registered in ClinicalTrials.gov with Ludwig-Maximilians - University of Munich as lead sponsor.

NCT NCT06642506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06642506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma.
Lead sponsor
Ludwig-Maximilians - University of Munich
Phase
Observational
Overall status
Active, not recruiting
Start date
October 6, 2024
Completion date
September 30, 2025
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemoresistance, esophagus adenocarcinoma, esophagus cancer, mass spectrometry, metabolome, metabolomics, oncology patients receiving chemotherapy, precision medicine